Ruiwen Zhang
#175,866
Most Influential Person Now
Ruiwen Zhang's AcademicInfluence.com Rankings
Ruiwen Zhangcomputer-science Degrees
Computer Science
#10895
World Rank
#11488
Historical Rank
Machine Learning
#4967
World Rank
#5027
Historical Rank
Artificial Intelligence
#5348
World Rank
#5420
Historical Rank
Database
#7896
World Rank
#8219
Historical Rank
Download Badge
Computer Science
Ruiwen Zhang's Degrees
- Bachelors Computer Science Stanford University
- Masters Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Ruiwen Zhang Influential?
(Suggest an Edit or Addition)According to Wikipedia, Ruiwen Zhang is a Chinese-American pharmaceutical scientist and is Robert L. Boblitt Endowed Professor in Drug Discovery currently at University of Houston. He is Elected Fellow of the American Association for the Advancement of Science.
Ruiwen Zhang's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action (2008) (314)
- In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng (2007) (291)
- Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure–Activity Relationships, and Molecular Mechanisms of Action (2012) (279)
- Anti-Inflammatory Agents for Cancer Therapy. (2009) (269)
- Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. (2007) (263)
- The MDM2-p53 pathway revisited (2013) (258)
- MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. (2005) (254)
- MDM2 Is a Negative Regulator of p21WAF1/CIP1, Independent of p53* (2004) (253)
- Wnt/beta-catenin signaling pathway as a novel cancer drug target. (2004) (242)
- Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy (2003) (198)
- Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? (2008) (173)
- Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy (2008) (168)
- MSP–RON signalling in cancer: pathogenesis and therapeutic potential (2013) (163)
- Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. (2014) (158)
- Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications (2015) (154)
- Targeting the NFκB signaling pathways for breast cancer prevention and therapy. (2014) (146)
- Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation (2008) (146)
- Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis (2006) (134)
- Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway (2005) (129)
- Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. (2005) (127)
- Differential effects of ginsenosides on NO and TNF-α production by LPS-activated N9 microglia (2007) (121)
- Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV‐infected subjects (1995) (119)
- p53-independent activities of MDM2 and their relevance to cancer therapy. (2005) (108)
- Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts (2004) (107)
- Experimental therapy of prostate cancer with novel natural product anti‐cancer ginsenosides (2008) (106)
- Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. (2014) (105)
- Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications (2015) (99)
- NFAT as cancer target: mission possible? (2014) (98)
- Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. (2009) (95)
- Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5‐fluorouracil chemotherapy (1995) (89)
- Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms (2003) (88)
- Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression (1999) (85)
- Molecular targeting therapies for neuroblastoma: Progress and challenges (2020) (84)
- RYBP stabilizes p53 by modulating MDM2 (2009) (80)
- Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2 (2012) (75)
- Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I (1998) (71)
- Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. (2007) (70)
- Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. (2005) (68)
- Chemotherapy and chemosensitization of non–small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9 (2006) (67)
- Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. (2009) (66)
- The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models (2014) (63)
- Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. (2014) (62)
- Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. (2003) (62)
- Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models (2004) (61)
- Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. (2011) (61)
- Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP (2012) (61)
- Structure-Activity Relationship and Substrate-Dependent Phenomena in Effects of Ginsenosides on Activities of Drug-Metabolizing P450 Enzymes (2008) (61)
- Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia. (2007) (61)
- Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine (2018) (58)
- In vitro and In vivo Anticancer Activity of Novel Synthetic Makaluvamine Analogues (2009) (57)
- Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti‐MDM2 Oligonucleotides (2003) (53)
- The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells (2011) (52)
- Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action (2015) (51)
- Extracellular Activity of Cyclic AMP–Dependent Protein Kinase as a Biomarker for Human Cancer Detection: Distribution Characteristics in a Normal Population and Cancer Patients (2007) (51)
- Transcription Factor NFAT1 Activates the mdm2 Oncogene Independent of p53* (2012) (51)
- Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation (2014) (50)
- Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein (2011) (48)
- Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents (2013) (48)
- RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo (2014) (47)
- Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms (2002) (47)
- Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. (2002) (45)
- Targeting MDM2 for novel molecular therapy: Beyond oncology (2020) (45)
- Recent advances in validating MDM2 as a cancer target. (2009) (45)
- Novel natural product therapeutics targeting both inflammation and cancer. (2017) (45)
- Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells (2013) (40)
- Japonicone A Suppresses Growth of Burkitt Lymphoma Cells through Its Effect on NF-κB (2013) (39)
- JKA97, a Novel Benzylidene Analog of Harmine, Exerts Anti-Cancer Effects by Inducing G1 Arrest, Apoptosis, and p53-Independent Up-Regulation of p21 (2012) (39)
- MDM2 Promotes Proteasomal Degradation of p21Waf1 via a Conformation Change* (2010) (39)
- Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. (2012) (39)
- Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine (2004) (38)
- Experimental Therapy of Ovarian Cancer with Synthetic Makaluvamine Analog: In Vitro and In Vivo Anticancer Activity and Molecular Mechanisms of Action (2011) (38)
- Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. (2007) (38)
- Knockdown of ribosomal protein S7 causes developmental abnormalities via p53 dependent and independent pathways in zebrafish. (2011) (37)
- Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy (2006) (37)
- MDM 2 Is a Negative Regulator of p 21 WAF 1 / CIP 1 , Independent of p 53 * (2004) (37)
- A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability (2006) (36)
- Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. (2005) (35)
- A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action (2010) (35)
- Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein (2017) (34)
- Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. (2020) (33)
- miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. (2013) (32)
- Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz. (2013) (32)
- KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology (2012) (32)
- Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. (2002) (32)
- T40214/PEI complex: A potent therapeutics for prostate cancer that targets STAT3 signaling (2008) (32)
- Oncogenes as Novel Targets for Cancer Therapy (Part I) (2005) (31)
- Brain- and brain tumor-penetrating disulfiram nanoparticles: Sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts (2017) (31)
- CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. (2003) (31)
- Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. (2018) (31)
- Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. (2002) (30)
- Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors (2010) (29)
- MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. (2019) (29)
- FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer (2010) (28)
- Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy (2009) (28)
- Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA (2015) (28)
- Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy (2014) (27)
- Prevention of BMS‐777607‐induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics (2014) (26)
- Novel MDM2 p53‐Independent Functions Identified through RNA Silencing Technologies (2005) (26)
- Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor. (2013) (26)
- Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes. (2017) (25)
- A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance (2019) (25)
- Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. (2002) (25)
- Radiolabeled 2′-fluorodeoxyuracil-β-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-β-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice (2002) (25)
- Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin45–132 inhibit the growth of prostate cancer (2009) (25)
- RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. (2015) (25)
- Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. (2016) (24)
- Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction (2013) (24)
- Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen (2017) (24)
- Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI a subunit of protein kinase A after oral administration (1999) (23)
- Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy (2016) (23)
- CTLA-4 interferes with the HBV-specific T cell immune response (Review) (2018) (22)
- RNF185 modulates JWA ubiquitination and promotes gastric cancer metastasis. (2018) (22)
- Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: Effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy (2006) (21)
- Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy (2016) (21)
- Oncogenes as Novel Targets for Cancer Therapy (Part IV) (2005) (21)
- Preclinical Pharmacology of BA-TPQ, a Novel Synthetic Iminoquinone Anticancer Agent (2010) (21)
- Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms (2018) (20)
- Synthesis and In Vitro Anti-Lung Cancer Activity of Novel 1, 3, 4, 8- Tetrahydropyrrolo (4, 3, 2-de)quinolin-8(1H)-o ne Alkaloid Analogs (2009) (20)
- Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. (2002) (19)
- Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent (2005) (19)
- Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging (2019) (19)
- Recent advances in experimental molecular therapeutics for malignant gliomas. (2004) (19)
- Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog (2012) (18)
- Antisense-based cancer therapeutics: are we there yet? (2006) (17)
- Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy (2018) (17)
- Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents (2005) (16)
- Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. (2016) (16)
- Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer (2007) (15)
- Multifaceted roles of 5'-regulatory region of the cancer associated gene B4GALT1 and its comparison with the gene family. (2015) (15)
- Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. (2017) (14)
- JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin αvβ3 signaling (2020) (14)
- Synergistic activation of p 53 by inhibition of MDM 2 expression and DNA damage (1997) (14)
- Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer (2016) (13)
- Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer (2016) (12)
- Oncogenes as Novel Targets for Cancer Therapy (Part III) (2005) (11)
- Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. (2015) (11)
- Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents (2017) (10)
- Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs. (2009) (10)
- BCCIPβ modulates the ribosomal and extraribosomal function of S7 through a direct interaction (2017) (10)
- Anticancer Activity and Molecular Mechanisms of Action of Makaluvamines and Analogues (2012) (9)
- QSAR studies of new pyrido[3,4-b]indole derivatives as inhibitors of colon and pancreatic cancer cell proliferation (2018) (9)
- Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents. (2013) (9)
- Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action (2020) (9)
- Discovery and development of synthetic tricyclic pyrroloquinone (TPQ) alkaloid analogs for human cancer therapy (2016) (9)
- Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl (2006) (8)
- Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ. (2013) (8)
- The role of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (dthdPase) in the circadian variation of plasma drug levels of 5-fluorouracil (FUra) and 5-fluorodeoxyuridine (FdUrd) following infusion of FUra or FdUrd (1990) (8)
- Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. (2002) (8)
- Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice. (2011) (7)
- Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent (2012) (7)
- Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. (2020) (7)
- Antisense Anti-MDM 2 Oligonucleotides As a Novel Therapeutic Approach to Human Breast Cancer : In Vitro and in Vivo Activities and Mechanisms 1 (2001) (7)
- RNA Silencing Technologies in Drug Discovery and Target Validation (2005) (7)
- Antisense oligonucleotide inhibitors of MDM2 oncogene expression. (2003) (7)
- Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy † (2020) (7)
- A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study. (2014) (6)
- Oncogenes as Novel Targets for Cancer Therapy (Part II) (2005) (6)
- Antisense approaches in drug discovery and development. (2005) (6)
- Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth (2021) (6)
- Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. (2006) (6)
- Transcription factor NFAT 1 activates the mdm 2 oncogene independent of p 53 * (2012) (5)
- RYBP stabilizes p 53 by modulating MDM 2 (2013) (5)
- Genomic Space of MGMT in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression (2021) (4)
- Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies (2005) (4)
- Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action (2020) (4)
- A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors (2007) (4)
- Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models. (2016) (3)
- Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. (2015) (3)
- Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases. (2015) (3)
- Anticancer 20(R)-dammarane-3β,12β,20,25-tetrol-loaded polymeric micelles: Preparation, quantification and pharmacokinetics. (2016) (3)
- Antisense oligonucleotides as anti-tumor therapeutics (2000) (2)
- Editorial (Hot Topic: Anti-cancer Molecular Targets of Natural Products) (2013) (2)
- Modulation of gene expression by antisense oligonucleotides (2002) (2)
- Preclinical studies with dihydronaphthalene monophenol (NSC D725087), a vascular targeting agent, and its monophosphate prodrug (NSC D725088). (2004) (2)
- Anti-cancer molecular targets of natural products. (2013) (2)
- Effects of dexamethasone (Dex) pretreatment on toxicity and efficacy of carboplatin and gemcitabine (Carbo/Gem) in patients with non-small cell lung cancer (NSCLC) (2007) (1)
- Corrigendum to "A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance" [Genes Dis 694 (2019) 419-430]. (2020) (1)
- Characterization of regulatory sequences in alternative promoters of hypermethylated genes associated with tumor resistance to cisplatin. (2015) (1)
- Abstract LB-269: Anti-RON antibody-drug maytansinoid conjugates (Anti-RON ADC) as potential biotherapeutics for targeted colorectal cancer therapy (2014) (1)
- Preface: Scientific Premise and Rigors in Scientific Research, Peer Review, Editing and Publishing. (2016) (1)
- UCHL1 promotes cancer stemness in triple-negative breast cancer. (2022) (1)
- Drug for pancreatic cancer heralds a new strategy for fighting cancer (2020) (0)
- The role of p53 and p21 in cancer therapy with MDM2 inhibitor. (2004) (0)
- ANTISENSE STRATEGIES FOR THE DEVELOPMENT OF NOVEL CANCER THERAPEUTICS (2006) (0)
- QSAR studies of new pyrido[3,4-b]indole derivatives as inhibitors of colon and pancreatic cancer cell proliferation (2018) (0)
- ExperimentalTherapy of Hepatomawith Artemisinin and Its Derivatives : In vitro and In vivo Activity , Chemosensitization , andMechanisms of Action (2008) (0)
- Linkage between Toxicology of Drugs and Metabolism (2010) (0)
- Abstract 4867: Treating hepatocellular carcinoma metastasis and overcoming chemoresistance through inhibiting the MDM2 oncogene (2018) (0)
- Abstract 3834: JKA97, a novel anti-cancer candidate, induces G1 arrest via up-regulation of p21 in a p53-independent manner (2012) (0)
- Abstract C93: RYBP predicts survival of patients with non-small cell lung cancer and sensitizes chemotherapy (2015) (0)
- Editorial: looking forward to another successful year. (2014) (0)
- Targeting NFAT1–MDM2–p53 pathway for cancer therapy (2016) (0)
- Abstract 4863: Targeting the NFAT1-MDM2-MDMX network for prostate cancer therapy (2018) (0)
- Abstract 3605: Enterohepatic circulation of indolecarboxamide ML-970 (NSC 716970), an investigative anticancer agent (2010) (0)
- Abstract 3107: Novel molecular mechanisms of MDM2-induced p21Waf1degradation (2010) (0)
- Structural studies of antitumor compounds that target the RING domain of MDM2 (2022) (0)
- The structure-activity relationship (SAR) of and novel molecular mechanisms for ginsenosides as anticancer agents (2006) (0)
- Cancer Therapy : Preclinical JaponiconeASuppressesGrowth of Burkitt LymphomaCells through Its Effect on NFk B (2013) (0)
- Abstract 2434: The anticancer activity of Japonicone A is mediated by inhibiting NFAT1-MDM2 pathway (2015) (0)
- Development of new therapeutic agents for the treatment of triple negative breast cancer (2021) (0)
- Antisense Oligonucleotides Targeting RIα Subunit of Protein Kinase A (2003) (0)
- Abstract 926: Experimental therapy of pancreatic cancer with KCN1, a novel anticancer agent targeting HIF-1α pathway (2012) (0)
- Abstract 1996: Anticancer efficacy and mechanism of action of novel ginsenoside 25-OCH3-PPD, a natural product MDM2 inhibitor (2012) (0)
- A phase I trial of an anti-pka oligonucleotide (GEM231) administered with weekly CPT-11 (2004) (0)
- Abstract 5266: RYBP expression predicts survival of patients with hepatocellular carcinoma, and regulates response to chemotherapy (2015) (0)
- Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer (2016) (0)
- Erratum: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Clinical Pharmacology and Therapeutics (1995) 58 (44-53) DOI: 10.1016/0009-9236(95)90071-3) (2011) (0)
- Abstract 1189: Discovery of RPS25-MDM2/MDMX-p53 regulatory feedback loop (2012) (0)
- Abstract 2786: Targeting oncogene and inflammation for cancer therapy (2023) (0)
- Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer (2016) (0)
- Abstract 2433: A novel MDM2 inhibitor suppresses breast cancer growth and metastasis (2015) (0)
- Abstract 1980: Dihydroartemisinin inhibits ovarian cancer growth and metastasis via targeting PDGFRα (2012) (0)
- A phase I study of bi-weekly administration of 24-hr gemcitabine (GEM) followed by 24-hr irinotecan (CPT-11) in patients with solid tumors (2005) (0)
- Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging (2019) (0)
- Identification and clinical prognosis of salinomycin binding targets in neuroblastoma (LB613) (2014) (0)
- MDM2 is a direct, p53-independent, negative regulator of p21 (2004) (0)
- Abstract 4614: Identification of two salinomycin binding targets in neuroblastoma (2014) (0)
- Editorial [Hot Topic: MDM2 as a Cancer Therapeutic Target (Guest Editor: Ruiwen Zhang)] (2005) (0)
- Abstract 3858: Inflammation and oncogene in hepatocellular carcinoma: Clinical relevance and experimental targeted therapy (2019) (0)
- Preclinical evaluation of anti-RON antibody-drug maytansinoid conjugates (anti-RON ADC) for targeted colorectal cacner therapy. (2014) (0)
- Cancer Therapy : Preclinical Arylsulfonamide KCN 1 Inhibits In Vivo Glioma Growth and Interfereswith HIF Signaling byDisrupting HIF-1 a Interaction with Cofactors p 300 / CBP (2012) (0)
- Abstract 1075: Multiple alternative promoters and a long non-coding RNA constitute the complex regulatory region of the cancer and drug resistance associated gene B4GALT1 (2015) (0)
- Cancer Therapy : Preclinical Ef fi cacy of Anti-RON Antibody Zt / g 4 – Drug Maytansinoid Conjugation ( Anti-RON ADC ) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy (2014) (0)
- Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Science (2014) (0)
- Antisense oligonucleotides targeting RI alpha subunit of protein kinase A. In vitro and in vivo anti-tumor activity and pharmacokinetics. (2003) (0)
This paper list is powered by the following services:
Other Resources About Ruiwen Zhang
What Schools Are Affiliated With Ruiwen Zhang?
Ruiwen Zhang is affiliated with the following schools:
